The Wall Street Journal: Valeant Pharmaceuticals to buy Salix for about $10 billion

Valeant Pharmaceuticals International Inc. said Sunday it would buy Salix Pharmaceuticals Ltd. for about $10 billion, a return to its big deal-making ways after a failed bid for Botox maker Allergan Inc. last year.